TEVA

Market-moving news on Teva Pharmaceutical Industries (NYSE: TEVA): filings, earnings, deals and other events, from REDFILED.

TEVA

TEVA Posts New SOLARIS Data on Monthly Olanzapine Shot Ahead of FDA Call

Post hoc analysis shows 56% of patients on TEV-'749 reached stabilization, with a PDUFA decision due in the fourth quarter of 2026.

TEVA

TEVA Prices $4.9 Billion of Senior Notes to Refinance Costlier Debt

Teva priced five tranches of euro- and dollar-denominated senior notes at coupons of 4.25% to 5.75% and will use the proceeds to redeem bonds carrying up to 8.125%.